Trials / Not Yet Recruiting
Not Yet RecruitingNCT07294872
A Study of TIL in Advanced Solid Tumors (CZ)
A Study Study of Tumor Infiltrating Lymphocytes Injection (GC101/203 TIL) in Patients With Advanced Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Shanghai Juncell Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs and gene-edited TILs are expanded from tumor resections and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GC101TIL | A tumor sample is resected from each participant and cultured ex vivo to expand the population of Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL). After lymphodepletion, patients are infused GC101 TIL. |
Timeline
- Start date
- 2026-05-08
- Primary completion
- 2026-09-20
- Completion
- 2029-09-20
- First posted
- 2025-12-19
- Last updated
- 2026-01-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07294872. Inclusion in this directory is not an endorsement.